Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07636811 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
A Phase 2 study, sponsored by Alnylam Pharmaceuticals.
- Not yet
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT07636811 is a Phase 2 study that has not yet begun recruiting, run by Alnylam Pharmaceuticals. The registered enrollment target is 58 participants.
The verdict
NCT07636811, a Phase 2 study, has not yet begun recruiting, sponsored by Alnylam Pharmaceuticals.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the effect of mivelsiran in adult participants with early-stage DS-AD and to characterize the safety, tolerability, and pharmacodynamics (PD) of mivelsiran. The study will be conducted over 2 periods: a 24-month double-blind period and an optional 12-month open-label treatment extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 39 months.
Interventions
- DRUG Placebo
- DRUG Mivelsiran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2031-07-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07636811
The ClinicalTrials.gov registry entry for NCT07636811 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07636811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07636811 about?
NCT07636811 is a clinical study titled "A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)". The purpose of the study is to evaluate the effect of mivelsiran in adult participants with early-stage DS-AD and to characterize the safety, tolerability, and pharmacodynamics (PD) of mivelsiran. The study will be conducted over 2 periods: a 24-month double-blind period and an optional 12-month ope...
What is the current status of trial NCT07636811?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2026-07-01. Estimated completion is 2031-07-23.
What interventions are being tested in trial NCT07636811?
The interventions under investigation include: Placebo (DRUG), Mivelsiran (DRUG).
Who is sponsoring clinical trial NCT07636811?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.